Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Actavia Life Sciences Inc (PK) | RASP | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.0173 | 11:33:21 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.0173 | 0.0173 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 0.0062 - 0.0319 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.0173 | USD |
Actavia Life Sciences Inc (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 13.35M | 771.81M | 37.00M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Actavia Life Sciences (PK) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RASP Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.0173 | 0.0173 | 0.0173 | 0.0173 | 120 | 0.00 | 0.00% |
| 1 Month | 0.008 | 0.0173 | 0.0078 | 0.0078754 | 7,560 | 0.0093 | 116.25% |
| 3 Months | 0.0179 | 0.0179 | 0.0077 | 0.0079406 | 3,869 | -0.0006 | -3.35% |
| 6 Months | 0.0077 | 0.019 | 0.0077 | 0.0079664 | 2,801 | 0.0096 | 124.68% |
| 1 Year | 0.0062 | 0.0319 | 0.0062 | 0.0163555 | 7,847 | 0.0111 | 179.03% |
| 3 Years | 0.0999 | 0.135 | 0.0001 | 0.0275918 | 13,512 | -0.0826 | -82.68% |
| 5 Years | 0.06 | 0.33 | 0.0001 | 0.0488396 | 31,449 | -0.0427 | -71.17% |
Actavia Life Sciences (PK) Description
| Rasna Therapeutics, Inc. (OTC:RASP), a development stage biotechnology company focused on the development of cancer drugs, today announced the successful completion of its merger. Rasna Therapeutics, Inc. is a development stage biotechnology company focused primarily on the development of drug candidates for leukemia and lymphoma. Abnormal epigenetic modification is recognized to play an important role in the pathogenesis of acute myeloid leukemia (AML), leading to silencing of genes involved in tumor suppression and cellular reproduction. Rasna's focus on inhibition of lysine specific demethylase-1 (LSD1), an enzyme involved in epigenetic control, represents a promising and novel approach towards AML. Rasna has developed novel irreversible and reversible LSD1 regulators that have shown appropriate effects on the LSD1 gene in-vitro and in IND-enabling pre-clinical studies. |
